Dec003m

Phase 1

HHangzhou DAC Biotechnology Co., Ltd.

Dec003m is one of 3 therapeutic programs targeting Advanced Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Prostate CancerNot yet recruiting

Advanced Prostate CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Advanced Prostate Cancer

#DrugCompanyPhaseTrials

XNW5004

EEvopoint Biosciences Inc.

Phase 2

1 2

HRS-5041

JJiangsu HengRui Medicine Co., Ltd.

Phase 1

1 3

Dec003m

HHangzhou DAC Biotechnology Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 1Not yet recruiting

Advanced Prostate Cancer

NCT07657806

Clinical

Trials by Indication[1]

Advanced Prostate Cancer1 trial

A Phase 1 Study of DEC003M, an Antibody Drug Conjugate Targeting PSMA, for Advanced Stage Prostate Cancer

Not yet recruiting·HHangzhou DAC Biotechnology Co., Ltd.·Phase 1·NCT07657806·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dec003m. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dec003m. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hangzhou DAC Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHangzhou DAC Biotechnology Co., Ltd.

Dec003m

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Advanced Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News